Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Govitecan and Ivonescimab in Previously-Treated AGA Positive Stage IV or Recurrent NSCLC (Lung-MAP Sub-Study)
NCT07393555Phase 2Recruiting
- Sponsor
- SWOG Cancer Research Network
- Start
- Sep 2026
- Primary completion
- Nov 2028
- Modality
- Small Molecules, Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab govitecan, ivonescimab in non-small cell lung cancer (NSCLC), sponsored by SWOG Cancer Research Network. Started Sep 2026; status: recruiting.
02
Drugs
sacituzumab govitecanivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07393555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07393555.